Alzheimer's disease and Dementia

Welcome Message

Welcome to the 18th International Conference on Alzheimer’s disease and Dementia. This conference is a unique opportunity to connect with experts, researchers, clinicians and advocates from around the world who are working to advance the understanding, prevention, diagnosis and treatment of dementia. You will learn about the latest scientific developments, best practices and innovations in the field of dementia care and support. You will also have the chance to network with peers, share your experiences and insights, and contribute to the global dementia movement. We are delighted to host this conference in the beautiful city of Paris, France, where you can enjoy the rich culture, history and cuisine of this amazing destination. We hope you will find this conference informative, inspiring and rewarding. Thank you for joining us and we look forward to meeting you soon.

Top Reasons to Be a Part of This Extravaganza:

• Stimulating Plenary Sessions: Prepare to be amazed by the visionary speeches of distinguished experts who will share their insights and wisdom on the most pressing issues and challenges in dementia care and research. You will learn from their experiences, successes and failures, and get inspired by their passion and vision.
• Cutting-Edge Symposia: Dive into a diverse range of topics that cover the latest advances and innovations in dementia science and practice. You will discover new knowledge, methods and tools that can help you improve your work and outcomes. You will also interact with speakers and attendees, and exchange ideas and opinions.
• Interactive Workshops: Enhance your skills and competencies through hands-on training sessions led by experienced facilitators. You will learn how to apply evidence-based practices, use effective strategies and techniques, and overcome common barriers and challenges. You will also receive feedback and guidance from experts and peers.
• Showcase Your Research: Showcase your research and get recognition for your achievements. You will have the opportunity to present your work in oral or poster format, and receive constructive comments and suggestions from reviewers and audience. You will also network with potential collaborators, funders and employers.
• Networking Extravaganza: Connect with like-minded professionals, researchers, practitioners and advocates from different sectors, disciplines and regions. You will build new relationships, expand your network, and explore opportunities for collaboration, partnership and career development.

Sessions and Tracks

Track: 1 Alzheimer’s disease Imaging

Track: 2 Animal Models and Translational Medicine

Track: 3 Alzheimer’s disease Diagnosis

Track: 4 Alzheimer’s disease and Type 2 Diabetes

Track: 5 Amyotrophic lateral sclerosis or ALS

Track: 6 Ataxia

Track: 7 Batten Disease

Track: 8 Care Practice and Awareness

Track: 9 Dementia

Track: 10 Front Temporal Dementia

Track: 11 Alzheimer’s disease

Track: 12 Geriatrics and Cognitive Disorder

Track: 13 Huntington’s disease

Track: 14 Multiple Sclerosis

Track: 15 Neurophysiology

Track: 16 Neurodegenerative Disease

Track: 17 Neurological disorders

Track: 18 Parkinson’s disease

Track: 19 Prion Disease

Track: 20 Space Neuroscience

Track: 21 Vascular Dementia

Track: 22 Bipolar Disorder and Schizophrenia

Track: 23 Psychiatry

Track: 24 Neurological Infections

Track: 25 Brain Injury

Track: 26 Behavioral Neuroscience

Track: 27 Neurosurgery and Spine

Track: 28 Paediatric Neurology

Track: 29 Molecular Genetics and Neurobiology

Track: 30 Neurogenesis

Track: 31 Clinical and Translational Neurology

Track: 32 Ophthalmology and Visual Neuroscience

Track: 33 Neuroscience and Artificial Intelligence

Track: 34 Brain Pathology and Oncology Research

Track: 35 Brain Stimulation and Imaging  

Target Audience

Neurologists: Medical doctors who specialize in the diagnosis, treatment, and management of neurological disorders, including Alzheimer's disease and dementia.

Researchers and Scientists: Professionals engaged in cutting-edge research related to neurology, Alzheimer's disease, dementia, and other cognitive disorders.

Clinicians: Healthcare professionals involved in the direct care and treatment of individuals with Alzheimer's disease and dementia.

Geriatricians: Doctors specializing in the care of elderly patients, including the diagnosis and management of cognitive disorders.

Psychiatrists and Psychologists: Professionals with expertise in mental health and cognitive functions, often involved in the assessment and treatment of dementia-related behavioral symptoms.

Neuroscientists: Researchers focused on understanding the brain's structure, function, and mechanisms underlying cognitive decline.

Nursing Professionals: Nurses specialized in geriatric care, dementia care, and related fields.

Pharmacologists: Experts in studying the effects of drugs and medications on neurological conditions, including Alzheimer's disease.

Healthcare Administrators: Professionals involved in managing healthcare facilities, policies, and resources related to neurology and dementia care.

Caregivers and Family Members: Individuals who provide care and support to patients with Alzheimer's disease and dementia, seeking information and resources to better understand and manage these conditions.

Pharmaceutical Industry Representatives: Professionals from pharmaceutical companies engaged in the development of medications and treatments for Alzheimer's disease and related disorders.

Academics and Educators: Individuals involved in teaching and educating others about neurology, Alzheimer's disease, and dementia.

Government and Policy Makers: Officials involved in shaping healthcare policies and regulations related to neurological disorders and dementia care.

Non-profit Organizations and Advocates: Representatives from organizations dedicated to raising awareness, providing support, and advocating for individuals with Alzheimer's disease and their families.

Students and Trainees: Medical students, graduate students, and trainees interested in neurology and related fields.

Market Analysis

Alzheimer's Diagnostics Market:

Alzheimer's Diagnostics (AD) Market by Diagnostic  Type (Brain Imaging [Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET) and Others], Genetic Testing, Blood Testing and Others ), according to end users (hospitals and clinics, diagnostic centers and others) and geographically, it is expected to reach a decent CAGR forecast by 2028 due to the increasing  incidence of brain injury, dementia and Alzheimer's disease and other diseases the growing burden of the world population.

The global market for Alzheimer's Diagnostics (AD) is projected to grow at a CAGR of 10.97% during the forecast period 2023 to 2028. The Alzheimer's disease (AD) Diagnostics Market is witnessing bullish growth of the market driven by factors such as the regulatory approvals for Alzheimer's disease (AD) diagnosis in the world. In addition, the increasing incidence of head trauma due to accidents, work injuries and the like, and the increasing geriatric population will increase the incidence of Alzheimer's disease, thereby increasing the demand for Alzheimer's disease diagnostic equipment worldwide. Furthermore, increasing research and development of new biomarkers, presence of key market players, increase in product launches and approvals, etc. will create a need for Alzheimer's disease diagnosis in the coming years. Therefore, the Alzheimer's disease (AD) Diagnostics Market is anticipated to grow at a substantial CAGR during the forecast period 2023 to 2028.

Dynamics of Alzheimer's disease (AD) Diagnostics Market:

One of the key aspects driving the disease market is the growing prevalence of dementia around the world. Alzheimer's disease is a form of dementia that affects memory, thinking, and behavior. Therefore, the increasing prevalence of dementia will increase the incidence of Alzheimer's disease and ultimately increase the need for related diagnostic equipment. For example, according to the World Health Organization (WHO), an estimated 55 million people worldwide will be diagnosed with dementia in 2022, more than 60% of whom live in low- and middle-income countries. In addition, as the proportion of older people in the population increases in almost all countries, this number is projected to increase to 78 million in 2030 and 139 million in 2050.

In addition, increasing regulatory approval of Alzheimer's disease (AD) diagnostics is expected to be another important driver for the Alzheimer's disease (AD) diagnostics market. Different product launches in this field are different markets driving the market growth.

For example, in May 2022, Fujirebio Diagnostics, a global leader in high quality in vitro diagnostics (IVD), received the green light from the US Food and Drug Administration (FDA) for its Lumipulse G β-Amyloid Ratio (1). -42/1-40), which is aimed at people with cognitive impairments aged 55 and over. The test has also been cited as a revolutionary device for faster verification of assets that meet an unmet need. Additionally, in February 2022, Diadem, a pure-play diagnostics company, received CE-IVD Mark for its non-invasive, plasma-based predictive blood test AlzoSure Predict, used for early detection of Alzheimer's disease (AD). Thus, the growing number of regulatory approvals for the diagnosis of Alzheimer's disease (AD) underscores the need for diagnostic tests due to the increasing prevalence of the disease, which is driving the overall market for Alzheimer's disease diagnosis. Period 2023-2028. Therefore, the factors listed above together will drive the overall Alzheimer's disease (AD) diagnosis market during the forecast period 2023-2028.  However, the high cost of brain imaging, stigma and lack of awareness for the diagnosis of the Alzheimer's disease and other factors could jeopardize the development of the Alzheimer's disease (AD) diagnosis market.

Alzheimer's disease (AD) diagnostics market has been negatively impacted during the COVID-19 pandemic due to the reduction in the number of diagnostic tests due to the massive spread of the COVID-19 infection in the world. Also, in order to contain the spread of the infection, governments around the world have enacted strict containment rules, resulting in a shortage of supply chains, raw materials and other resources in the market, leading to a reduction in the production of all medical devices. In addition, patients and doctors have postponed many scheduled surgeries, diagnostic tests, and visits to laboratories and other healthcare facilities to stop the spread of infection, reducing visits to hospitals and clinics for diagnosis and treatment. However, with the easing of quarantine restrictions and a return to normalcy in the economic landscape, the development of a COVID-19 vaccine has ushered in a process of economic recovery that has started the process of resuming regular health services in. B. Regular outpatient visits for treatment and diagnosis in hospitals, clinics and laboratories, which increases the demand for products in the Alzheimer's disease (AD) diagnostic equipment market.

Alzheimer’s Disease (AD) Diagnostic Market Segment Analysis:

Alzheimer's Diagnostics (AD) Market by Diagnostic Type (Brain Imaging [Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET) and Others], Genetic Testing, Blood Testing and Others), End User (Hospitals). And clinics, diagnostic centers and more) and geography (North America, Europe, Asia Pacific and rest of the world). In the diagnostic segment of the Alzheimer's Diagnostics (AD) market, the Computed Tomography (CT) segment is expected to account for a majority of revenue in 2021. This is mainly due to the great advantages of computed tomography (CT). . For example, CT scans are used to detect the loss of brain mass associated with Alzheimer's disease (AD) and provide a detailed look inside the brain. It also helps to collect more images of the brain area from different angles. In addition, the study helps distinguish Alzheimer's disease (AD) from other types of dementia such as vascular dementia, mixed dementia and others. In addition, the increasing use of CT scans for brain imaging is also increasing the market demand for Alzheimer's disease (AD) diagnosis. For example, in May 2021, Koninklijke Philips N.V., a global leader in medical technology, announced the launch of its Spectral Computed Tomography (CT) 7500 system, which is based on a breast detector. The system provides high-quality spectral images for each patient, including head and other scans. Therefore, given the benefits and applications associated with the CT segment and the increase in product launches, this category is expected to witness significant growth, ultimately contributing to the overall growth of the global Alzheimer's Diagnostics (MA) market over the forecast period will contribute.

North America is expected to dominate the overall Alzheimer's diagnostics market:

Across all regions, North America is expected to dominate the global medical device testing services in 2021 and will continue to do so during the forecast period 2023 to 2028 This is due to the growing incidence of traumatic brain injuries, increasing geriatric population, increasing product launch and approvals in the region, presence of key market players in the region, and other factors driving the demand for Alzheimer's disease (AD) diagnoses in the region region will increase. Specific forecast period. For example, according to the latest 2021 data from the American Society of Biochemistry and Molecular Biology, one brain injury occurs every nine seconds in the United States, resulting in more than 3.5 million accidents annually.Also, according to the above source and statistics, approximately 2.8 million people suffer traumatic brain injury (TBI) in the United States each year, of which 2.80,000 are hospitalized. As a result, more and more cases of head injuries, such as B. traumatic brain injury (TBI), associated with a high risk of developing Alzheimer's disease.

In addition, the increasing incidence of Alzheimer's disease in the United States will boost the diagnostic equipment market. According to the Alzheimer's Association (2023), more than 6 million Americans are living with Alzheimer's disease. That number is projected to increase to nearly 13 million by 2050. The increasing prevalence of Alzheimer's disease in the United States will increase the demand for diagnostic devices, ultimately leading to higher overall market growth.

Benefits of all Participation

Benefits of all Participation:   

• Access to all scientific sessions (lectures, plenary sessions, workshops, symposia, poster presentations)
• You will receive a membership from the International Organizing Committee (IOCM certificate)
• Complete conference package with conference souvenir and final program (e-copies)
• Abstracts are published in conference souvenirs and relevant international journals
• Each abstract is given a unique DOI number assigned by Cross Ref
• Commendable speeches from the highest level of the global scientific community
• A website for over 35,000 visitors in less than 6 months
• Keynote speeches by the world's top scientists
• Cutting-edge industry representation
• Symposia and reflections Inspiring workshops
• Outstanding awards and global recognition for outstanding scientists
• Best Poster Award nominations
• Outstanding Young Researcher Award geared towards best budding young research.
• Benefits of group registration (25% off)
• Advanced research-oriented presentations
• Collaboration between science and research. Industry
• Triumph of Awards, certificates recognize your dedication to your profession to encourage new research.
• Wide variety of exhibitors to showcase new and emerging technologies.
• A platform for a global investor community to connect with stakeholders.
• An excellent platform for product presentations and international sponsoring.
• The best platform to develop new partnerships and projects. Cooperation.
• The best position to speed up your journey to any area of ​​the world.
• 89% of our conference attendees are key contacts in their universities, companies, organizations, hospitals, medical centers, and laboratories when it comes to purchasing decisions related to the field of study.